Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Apr;40(4):999-1004.
doi: 10.1007/s00345-022-03928-1. Epub 2022 Jan 17.

Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial

Félix Guerrero-Ramos  1 , Daniel A González-Padilla  2 , Alejandro González-Díaz  2 , Federico de la Rosa-Kehrmann  2 , Alfredo Rodríguez-Antolín  2 , Brant A Inman  3 , Felipe Villacampa-Aubá  4
Affiliations
Clinical Trial

Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial

Félix Guerrero-Ramos et al. World J Urol. 2022 Apr.

Abstract

Purpose: The purpose of the study was to compare the outcomes of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) patients treated with BCG vs recirculating hyperthermic intravesical chemotherapy (HIVEC) with mitomycin C (MMC).

Methods: A pilot phase II randomized clinical trial was conducted including HR-NMIBC patients, excluding carcinoma in situ. Patients were randomized 1:1 to receive intravesical BCG for 1 year (once weekly for 6 weeks plus subsequent maintenance) or HIVEC with 40 mg MMC, administered using the Combat BRS system (once weekly instillations were given for 6 weeks, followed by once monthly instillation for 6 months). Total recirculating dwell time for HIVEC was 60 min at a target temperature of 43° ± 0.5 °C. Primary endpoint was recurrence-free survival. Secondary endpoints were time to recurrence, progression-free survival, cancer-specific survival, and overall survival at 24 months. Adverse events were routinely assessed.

Results: Fifty patients were enrolled. Mean age was 73.5 years. Median follow-up was 33.7 months. Recurrence-free survival at 24 months was 86.5% for HIVEC and 71.8% for BCG (p = 0.184) in the intention-to-treat analysis and 95.0% for HIVEC and 75.1% for BCG (p = 0.064) in the per protocol analysis. Time to recurrence was 21.5 and 16.1 months for HIVEC and BCG, respectively. Progression-free survival for HIVEC vs BCG was 95.7% vs 71.8% (p = 0.043) in the intention-to-treat analysis and 100% vs 75.1% (p = 0.018) in the per protocol analysis, respectively. Cancer-specific survival at 24 months was 100% for both groups and overall survival was 91.5% for HIVEC vs 81.8% for BCG.

Conclusion: HIVEC provides comparable safety and efficacy to BCG and is a reasonable alternative during BCG shortages.

Trial registration: EudraCT 2016-001186-85. Date of registration: 17 March 2016.

Keywords: Bacillus Calmette–Guérin; Bladder cancer; Hyperthermia; Progression; Recurrence.

PubMed Disclaimer

Conflict of interest statement

F. Guerrero-Ramos and B. A. Inman have received consultancy honoraria from Combat Medical Ltd.

Figures

Fig. 1
Fig. 1
Recurrence-free survival (RFS) curves in both treatment groups—ITT analysis
Fig. 2
Fig. 2
Progression-free survival (PFS) curves in both treatment groups—ITT analysis
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cambier S, Sylvester RJ, Collette L, et al. EORTC Nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–69. doi: 10.1016/j.eururo.2015.06.045. - DOI - PubMed
    1. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203. doi: 10.1016/j.juro.2009.07.016. - DOI - PubMed
    1. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63(3):462–472. doi: 10.1016/j.eururo.2012.10.039. - DOI - PubMed
    1. Schmidt S, Kunath F, Coles B, et al. Intravesical bacillus calmette-guérin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2020;1(1):CD011935. doi: 10.1002/14651858.CD011935.pub2. - DOI - PMC - PubMed
    1. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256. doi: 10.1016/j.eururo.2009.04.038. - DOI - PubMed

Publication types

MeSH terms